[go: up one dir, main page]

AR132470A1 - Inhibidor de lisina-acetiltransferasa 6a (kat6a), combinaciones y usos del mismo - Google Patents

Inhibidor de lisina-acetiltransferasa 6a (kat6a), combinaciones y usos del mismo

Info

Publication number
AR132470A1
AR132470A1 ARP240100991A ARP240100991A AR132470A1 AR 132470 A1 AR132470 A1 AR 132470A1 AR P240100991 A ARP240100991 A AR P240100991A AR P240100991 A ARP240100991 A AR P240100991A AR 132470 A1 AR132470 A1 AR 132470A1
Authority
AR
Argentina
Prior art keywords
kat6a
inhibitor
acetyltransferase
lysine
combinations
Prior art date
Application number
ARP240100991A
Other languages
English (en)
Inventor
Xin Cai
Man Zhang
Xin Cheng
Luoheng Qin
Feng Ren
Original Assignee
Insilico Medicine Ip Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insilico Medicine Ip Ltd filed Critical Insilico Medicine Ip Ltd
Publication of AR132470A1 publication Critical patent/AR132470A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Oncology (AREA)

Abstract

En la presente se describen métodos para tratar el cáncer usando un inhibidor de lisina acetiltransferasa 6a (KAT6A) de molécula pequeña y un agente adicional. Un método para tratar cáncer en un sujeto en necesidad del mismo, el método que comprende administrar al sujeto: (a) un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo.
ARP240100991A 2023-04-19 2024-04-19 Inhibidor de lisina-acetiltransferasa 6a (kat6a), combinaciones y usos del mismo AR132470A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023089277 2023-04-19
CN2024086020 2024-04-03

Publications (1)

Publication Number Publication Date
AR132470A1 true AR132470A1 (es) 2025-07-02

Family

ID=93151986

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100991A AR132470A1 (es) 2023-04-19 2024-04-19 Inhibidor de lisina-acetiltransferasa 6a (kat6a), combinaciones y usos del mismo

Country Status (8)

Country Link
KR (1) KR20250172879A (es)
CN (1) CN121335702A (es)
AR (1) AR132470A1 (es)
AU (1) AU2024259385A1 (es)
IL (1) IL323885A (es)
MX (1) MX2025012351A (es)
TW (1) TW202446378A (es)
WO (1) WO2024217563A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
RS64931B9 (sr) * 2019-06-18 2025-06-30 Pfizer Derivati benzizoxazol sulfonamida
AU2020295006B2 (en) * 2019-06-19 2023-11-09 Ctxt Pty Ltd Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives
PT4181920T (pt) * 2020-07-15 2025-11-04 Ctxt Pty Ltd Inibidor de kat6 e combinações para o tratamento do cancro da mama
EP4341259A4 (en) * 2021-05-21 2025-05-28 Aurigene Oncology Limited FUSED ISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS
CN118382622A (zh) * 2021-07-05 2024-07-23 杭州英创医药科技有限公司 作为kat6抑制剂的化合物
TW202334163A (zh) * 2021-11-16 2023-09-01 香港商英矽智能科技知識產權有限公司 離胺酸乙醯基轉移酶6a (kat6a)抑制劑及其用途

Also Published As

Publication number Publication date
KR20250172879A (ko) 2025-12-09
MX2025012351A (es) 2025-11-03
IL323885A (en) 2025-12-01
AU2024259385A1 (en) 2025-12-04
TW202446378A (zh) 2024-12-01
CN121335702A (zh) 2026-01-13
WO2024217563A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
AR127501A1 (es) Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
MX2024002538A (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t.
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
CO5590913A2 (es) Terapia de combinacion antivirica
DOP2024000146A (es) Inhibidores de parp7
CL2023000857A1 (es) Inhibidores line-1 para tratar la enfermedad
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
CL2022000781A1 (es) Tratamientos cognitivos medicinales
CO2025018532A2 (es) Un método para el tratamiento de tumores sólidos con un conjugado anticuerpo-fármaco dirigido a claudina 18.2
CO2025016753A2 (es) Inhibidores de gsk3α y métodos de uso de estos
AR127165A1 (es) Resmetirom para reducir el volumen del hígado
AR132470A1 (es) Inhibidor de lisina-acetiltransferasa 6a (kat6a), combinaciones y usos del mismo
MX2025006279A (es) Tratamientos contra el cancer mediante un inhibidor de prmt5 y un inhibidor de mat2a
AR131842A1 (es) Métodos para tratar gliomas
UY39593A (es) Tratamiento para tumores sólidos malignos
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
MX2022015532A (es) Inhibidores selectivos de hdac6 y usos de los mismos.
AR132852A1 (es) Combiterapia para tratar el cáncer
CL2025002792A1 (es) Compuesto y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores
CL2025001165A1 (es) Uso de compuestos activadores de guanilato ciclasa soluble para tratar esclerosis sistémica.
AR128539A1 (es) Terapias combinadas para el tratamiento de cánceres con moléculas de unión terapéuticas
AR133820A1 (es) Combinación de un inhibidor de wee1 y un inhibidor de pkmyt1